Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Xylem Inc. (XYL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

By ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / October 30, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Xylem Inc. ("Xylem" or "the Company") (NYSE:XYL). Investors who purchased Xylem securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/xylem-inc-xyl-investigation.

Xylem Investigation Details

On October 27, 2026, Xylem Inc. reported its third-quarter 2026 financial results, including revenue of approximately $2.20 billion, compared to estimates of roughly $2.28 billion, and adjusted earnings per share of $1.44, compared to analyst estimates of $1.45-$1.46. The Company also reduced its full-year 2026 revenue outlook by approximately $700 million to $8.95 billion and lowered its adjusted earnings per share guidance to $5.40-$5.45 from $5.55-$5.70. The Company had raised its earnings guidance the previous quarter and reaffirmed it on August 18, 2026, when announcing the appointment of a new Chief Financial Officer.

Following this news, Xylem's stock price dropped on October 27, 2026.

What's Next for Xylem Investors?

If you are aware of any facts relating to this investigation or purchased Xylem securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/xylem-inc-xyl-investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Xylem Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Xylem Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on ACCESS Newswire

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.